vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2022-1-15-22vtio-1469Research ArticleКлиническая трансплантологияClinical TransplantologyТрансплантация печени пациентам с первичным билиарным холангитом (обзор литературы)Liver transplantation for primary biliary cholangitis (review)ИльинскийИ. М.IljinskyI. M.

Ильинский Игорь Михайлович

123182, Москва, ул. Щукинская, д. 1

Тел. (999) 877-60-95

 

Igor Iljinsky.

1, Shchukinskaya str., Moscow, 123182

Phone: (999) 877-60-95

 

iiljinsky@mail.ruЦирульниковаО. М.TsirulnikovaO. M.

Москва

Moscow

tsiroulnikova@mail.ruФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииРоссияShumakov National Medical Research Center of Transplantology and Artificial OrgansRussian FederationФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава России; ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Минздрава России (Сеченовский университет)РоссияShumakov National Medical Research Center of Transplantology and Artificial Organs; Sechenov UniversityRussian Federation2022100220222411522Copyright © Ильинский И.М., Цирульникова О.М., 20222022Ильинский И.М., Цирульникова О.М.Iljinsky I.M., Tsirulnikova O.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/1469

Первичный билиарный холангит (ПБХ) – аутоиммунное заболевание печени, при котором происходит разрушение и воспаление внутрипеченочных желчных протоков. Ранее это заболевание в терминальной стадии было наиболее частой причиной трансплантации печени. Использование при лечении в качестве препарата первой линии урсодезоксихолевой кислоты и препарата второй линии – обетихоловой кислоты замедляет прогрессирование заболевания. Однако примерно у 40% пациентов с ПБХ лечение оказывается неэффективным, и заболевание может прогрессировать до цирроза и терминальной стадии заболевания печени. Этим пациентам для сохранения жизни проводят трансплантацию печени. После операции возможно развитие рекуррентного ПБХ, которое протекает в более легкой форме и редко вызывает необходимость в ретрансплантации печени.

Primary biliary cholangitis (PBC) is an autoimmune liver disease resulting from the destruction and inflammation of intrahepatic bile ducts. This end-stage disease was once the most common cause of liver transplantation. The use of ursodeoxycholic and obeticholic acids as a first-line and second-line treatment, respectively, slows down the disease. However, treatment is not effective in about 40% of PBC patients, and the disease may progress to cirrhosis and end-stage liver disease. These patients undergo liver transplantation to save their lives. After surgery, recurrent PBC can develop in a milder form and rarely requires liver retransplantation.

первичный билиарный холангитПБХтрансплантация печенивозвратный ПБХфакторы рискаprimary biliary cholangitisPBCLiver transplantationrecurrence PBCrisk factorsReferencesMilkiewicz P. Liver transplantation in primary biliary cirrhosis. Clin Liver Dis. 2008; 12 (2): 461–472. doi: 10.1016/j.cld.2008.02.015.Milkiewicz P. Liver transplantation in primary biliary cirrhosis. Clin Liver Dis. 2008; 12 (2): 461–472. doi: 10.1016/j.cld.2008.02.015.Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012 May; 56 (5): 1181–1188. doi: 10.1016/j.jhep.2011.10.025.Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol. 2012 May; 56 (5): 1181–1188. doi: 10.1016/j.jhep.2011.10.025.Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis. Semin Liver Dis. 2014 Aug; 34 (3): 318–328. doi: 10.1055/s-0034-1383730.Griffiths L, Dyson JK, Jones DE. The new epidemiology of primary biliary cirrhosis. Semin Liver Dis. 2014 Aug; 34 (3): 318–328. doi: 10.1055/s-0034-1383730.Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ et al. Im-proved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009; 136: 1281–1287.Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ et al. Im-proved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology. 2009; 136: 1281–1287.Schoning W, Schmeding M, Ulmer F, Andert A, Neumann U. Liver transplantation for patients with cholestatic liver diseases. Viszeralmedizin. 2015; 31: 194–198. doi: 10.1159/000431017.Schoning W, Schmeding M, Ulmer F, Andert A, Neumann U. Liver transplantation for patients with cholestatic liver diseases. Viszeralmedizin. 2015; 31: 194–198. doi: 10.1159/000431017.Sun CK, Chen CL, Concejero AM, Wang CC, Wang SH, Liu YW et al. Liver transplantation for primary biliary cirrhosis in a hepatitis endemic region: a single-center Asian experience. Clinical Transplantation. 2011; 25: 47–53. doi: 10.1111/j.1399-0012.2010.01288.x.Sun CK, Chen CL, Concejero AM, Wang CC, Wang SH, Liu YW et al. Liver transplantation for primary biliary cirrhosis in a hepatitis endemic region: a single-center Asian experience. Clinical Transplantation. 2011; 25: 47–53. doi: 10.1111/j.1399-0012.2010.01288.x.Harms MH, Janssen QP, Adam R, Duvoux C, Mirza D, Hidalgo E et al. European Liver and Intestine Transplant Association (ELITA). Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. Aliment Pharmacol Ther. 2019 Feb; 49 (3): 285–295. doi: 10.1111/apt.15060.Harms MH, Janssen QP, Adam R, Duvoux C, Mirza D, Hidalgo E et al. European Liver and Intestine Transplant Association (ELITA). Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades. Aliment Pharmacol Ther. 2019 Feb; 49 (3): 285–295. doi: 10.1111/apt.15060.Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2007 Nov; 5 (11): 1313–1315. doi: 10.1016/j.cgh.2007.07.015.Lee J, Belanger A, Doucette JT, Stanca C, Friedman S, Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2007 Nov; 5 (11): 1313–1315. doi: 10.1016/j.cgh.2007.07.015.Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006; 130 (3): 715–720. doi: 10.1053/j.gastro.2005.12.029.Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006; 130 (3): 715–720. doi: 10.1053/j.gastro.2005.12.029.Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008; 48 (3): 871–877. doi: 10.1002/hep.22428.Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008; 48 (3): 871–877. doi: 10.1002/hep.22428.Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL et al. Global PBC Study Group. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014 Dec; 147 (6): 1338–1349.e5; quiz e15. doi: 10.1053/j.gastro.2014.08.029.Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL et al. Global PBC Study Group. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014 Dec; 147 (6): 1338–1349.e5; quiz e15. doi: 10.1053/j.gastro.2014.08.029.Poupon R, Ping C, Chretien Y, Corpechot C, Chazouilleres O, Simon T et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol. 2008; 49: 1038–1045.Poupon R, Ping C, Chretien Y, Corpechot C, Chazouilleres O, Simon T et al. Genetic factors of susceptibility and of severity in primary biliary cirrhosis. J Hepatol. 2008; 49: 1038–1045.Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol. 2009; 31: 283–307.Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin Immunopathol. 2009; 31: 283–307.Akamatsu N, Sugawara Y. Primary biliary cirrhosis and liver transplantation. Intractable & Rare Diseases Research. 2012; 1: 66–80. doi: 10.5582/irdr.2012.v1.2.66.Akamatsu N, Sugawara Y. Primary biliary cirrhosis and liver transplantation. Intractable & Rare Diseases Research. 2012; 1: 66–80. doi: 10.5582/irdr.2012.v1.2.66.Aguilar MT, Carey EJ. Current Status of Liver Transplantation for Primary Biliary Cholangitis. Clin Liver Dis. 2018 Aug; 22 (3): 613–624. doi: 10.1016/j. cld.2018.03.011.Aguilar MT, Carey EJ. Current Status of Liver Transplantation for Primary Biliary Cholangitis. Clin Liver Dis. 2018 Aug; 22 (3): 613–624. doi: 10.1016/j. cld.2018.03.011.Ter Borg PC, Schalm SW, Hansen BE, van Buuren HR. Dutch PBC Study Group. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006 Sep; 101 (9): 2044–2050. doi: 10.1111/j.1572-0241.2006.00699.x.Ter Borg PC, Schalm SW, Hansen BE, van Buuren HR. Dutch PBC Study Group. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006 Sep; 101 (9): 2044–2050. doi: 10.1111/j.1572-0241.2006.00699.x.Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018 Sep; 67 (9): 1568–1594. doi: 10.1136/gutjnl-2017-315259.Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018 Sep; 67 (9): 1568–1594. doi: 10.1136/gutjnl-2017-315259.Chen L, Shi X, Lv G, Sun X, Sun C et al. The long-term outcomes of deceased-donor liver transplantation for primary biliary cirrhosis: a two-center study in China. PeerJ. 2020; 8: e9563. Published 2020 Aug 19. doi: 10.7717/peerj.9563.Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S et al. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018 Sep; 67 (9): 1568–1594. doi: 10.1136/gutjnl-2017-315259.Singal AK, Fang X, Kaif M, Hasanin M, Mcguire BM, Kuo YF, Wiesner RH. Primary biliary cirrhosis has high wait-list mortality among patients listed for liver trans plantation. Transpl Int. 2017 May; 30 (5): 454–462. doi: 10.1111/tri.12877.Chen L, Shi X, Lv G, Sun X, Sun C et al. The long-term outcomes of deceased-donor liver transplantation for primary biliary cirrhosis: a two-center study in China. PeerJ. 2020; 8: e9563. Published 2020 Aug 19. doi: 10.7717/peerj.9563.Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY et al. GLOBAL PBC Study Group. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. Hepatology. 2018 May; 67 (5): 1920–1930. doi: 10.1002/hep.29717.Singal AK, Fang X, Kaif M, Hasanin M, Mcguire BM, Kuo YF, Wiesner RH. Primary biliary cirrhosis has high wait-list mortality among patients listed for liver trans plantation. Transpl Int. 2017 May; 30 (5): 454–462. doi: 10.1111/tri.12877.Webb GJ, Rana A, Hodson J, Akhtar MZ, Ferguson JW, Neuberger JM et al. Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists. Clin Gastroenterol Hepatol. 2018 Feb; 16 (2): 278–287.e7. doi: 10.1016/j.cgh.2017.09.062.Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY et al. GLOBAL PBC Study Group. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. Hepatology. 2018 May; 67 (5): 1920–1930. doi: 10.1002/hep.29717.Lleo A, Jepsen P, Morenghi E, Carbone M, Moroni L, Battezzati PM et al. Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. Sci Rep. 2016 May 19; 6: 25906. doi: 10.1038/ srep25906.Webb GJ, Rana A, Hodson J, Akhtar MZ, Ferguson JW, Neuberger JM et al. Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists. Clin Gastroenterol Hepatol. 2018 Feb; 16 (2): 278–287.e7. doi: 10.1016/j.cgh.2017.09.062.Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant. 2010; 10: 720–726.Lleo A, Jepsen P, Morenghi E, Carbone M, Moroni L, Battezzati PM et al. Evolving Trends in Female to Male Incidence and Male Mortality of Primary Biliary Cholangitis. Sci Rep. 2016 May 19; 6: 25906. doi: 10.1038/ srep25906.Mac Quillan GC, Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis. 2003; 7: 941– 956.Silveira MG, Talwalkar JA, Lindor KD, Wiesner RH. Recurrent primary biliary cirrhosis after liver transplantation. Am J Transplant. 2010; 10: 720–726.Naik P, Sritharan V, Bandi P, Madhavarapu M. A single centre prospective study of liver function tests in post liver transplant patients. Indian Journal of Clinical Biochemistry. 2013; 28: 38–45. doi: 10.1007/s12291-012- 0245-4.Mac Quillan GC, Neuberger J. Liver transplantation for primary biliary cirrhosis. Clin Liver Dis. 2003; 7: 941– 956.Zhang W, Wang M, Xie HY, Zhou L, Meng XQ, Shi J, Zheng S. Role of reactive oxygen species in mediating hepatic ischemia-reperfusion injury and its therapeutic applications in liver transplantation. Transplantation Proceedings. 2007; 39: 1332–1337. doi: 10.1016/j.transproceed.2006.11.021.Naik P, Sritharan V, Bandi P, Madhavarapu M. A single centre prospective study of liver function tests in post liver transplant patients. Indian Journal of Clinical Biochemistry. 2013; 28: 38–45. doi: 10.1007/s12291-012- 0245-4.Li C, Wen TF, Mi K, Wang C, Yan LN, Li B. Analysis of infections in the first 3-month after living donor liver transplantation. World Journal of Gastroenterology. 2012; 18: 1975–1980. doi: 10.3748/wjg.v18.i16.1975.Zhang W, Wang M, Xie HY, Zhou L, Meng XQ, Shi J, Zheng S. Role of reactive oxygen species in mediating hepatic ischemia-reperfusion injury and its therapeutic applications in liver transplantation. Transplantation Proceedings. 2007; 39: 1332–1337. doi: 10.1016/j.transproceed.2006.11.021.Vera A, Contreras F, Guevara F. Incidence and risk factors for infections after liver transplant: single-center experience at the University Hospital Fundacion Santa Fe de Bogota, Colombia. Transplant Infectious Disease. 2011; 130: 608–615. doi: 10.1111/j.1399-3062.2011.00640.x.Li C, Wen TF, Mi K, Wang C, Yan LN, Li B. Analysis of infections in the first 3-month after living donor liver transplantation. World Journal of Gastroenterology. 2012; 18: 1975–1980. doi: 10.3748/wjg.v18.i16.1975.Wojcicki M, Milkiewicz P, Silva M. Biliary tract complications after liver transplantation: a review. Digestive Surgery. 2008; 25: 245–257. doi: 10.1159/000144653.Vera A, Contreras F, Guevara F. Incidence and risk factors for infections after liver transplant: single-center experience at the University Hospital Fundacion Santa Fe de Bogota, Colombia. Transplant Infectious Disease. 2011; 130: 608–615. doi: 10.1111/j.1399-3062.2011.00640.x.Khalaf H. Vascular complications after deceased and living donor liver transplantation: a single-center experience. Transplantation Proceedings. 2010; 42: 865–870. doi: 10.1016/j.transproceed.2010.02.037.Wojcicki M, Milkiewicz P, Silva M. Biliary tract complications after liver transplantation: a review. Digestive Surgery. 2008; 25: 245–257. doi: 10.1159/000144653.Mejia GA, Olarte-Parra C, Pedraza A, Rivera JB, Benavides CA. Biliary complications after liver transplantation: incidence. Risk factors and impact on patient and graft survival. Transplantation Proceedings. 2016; 48: 665–668. doi: 10.1016/j.transproceed.2016.02.033.Khalaf H. Vascular complications after deceased and living donor liver transplantation: a single-center experience. Transplantation Proceedings. 2010; 42: 865–870. doi: 10.1016/j.transproceed.2010.02.037.Ma L, Lu Q, Luo Y. Vascular complications after adult living donor liver transplantation: evaluation with ultrasonography. World Journal of Gastroenterology. 2016; 22: 1617–1626. doi: 10.3748/wjg.v22.i4.1617.Mejia GA, Olarte-Parra C, Pedraza A, Rivera JB, Benavides CA. Biliary complications after liver transplantation: incidence. Risk factors and impact on patient and graft survival. Transplantation Proceedings. 2016; 48: 665–668. doi: 10.1016/j.transproceed.2016.02.033.Kashyap R, Safadjou S, Chen R, Mantry P, Sharma R, Patil V et al. Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases – an analysis of the UNOS database. Journal of Gastrointestinal Surgery. 2010; 14: 1362–1369. doi: 10.1007/s11605-010-1256-1.Ma L, Lu Q, Luo Y. Vascular complications after adult living donor liver transplantation: evaluation with ultrasonography. World Journal of Gastroenterology. 2016; 22: 1617–1626. doi: 10.3748/wjg.v22.i4.1617.Liberal R, Zen Y, Mieli-Vergani G, Vergani D. Liver transplantation and autoimmune liver diseases. Liver Transplantation. 2013; 19: 1065–1077. doi: 10.1002/ lt.23704.Kashyap R, Safadjou S, Chen R, Mantry P, Sharma R, Patil V et al. Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases – an analysis of the UNOS database. Journal of Gastrointestinal Surgery. 2010; 14: 1362–1369. doi: 10.1007/s11605-010-1256-1.Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol. 2004; 99: 538–542.Liberal R, Zen Y, Mieli-Vergani G, Vergani D. Liver transplantation and autoimmune liver diseases. Liver Transplantation. 2013; 19: 1065–1077. doi: 10.1002/ lt.23704.Jacob DA, Neumann UP, Bahra M et al. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival. Transplant Proc. 2005; 37: 1691–1692.Maheshwari A, Yoo HY, Thuluvath PJ. Long-term outcome of liver transplantation in patients with PSC: a comparative analysis with PBC. Am J Gastroenterol. 2004; 99: 538–542.Jacob DA, Neumann UP, Bahra M et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transpl. 2006; 20: 211–220.Jacob DA, Neumann UP, Bahra M et al. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival. Transplant Proc. 2005; 37: 1691–1692.Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2004; 10: 488–491.Jacob DA, Neumann UP, Bahra M et al. Long-term follow-up after recurrence of primary biliary cirrhosis after liver transplantation in 100 patients. Clin Transpl. 2006; 20: 211–220.Ziarkiewlcz-Wrobiewska B, Wroblewskl T, Wasiutynski A. Morphological features and differential diagnosis of hepatitis C recurrence after liver transplantation – literature review and results of single transplantation center. Ann Transplant. 2008; 13 (2): 12–20.Neuberger J, Gunson B, Hubscher S, Nightingale P. Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2004; 10: 488–491.Charatcharoenwitthaya P, Pimentel S, Talwalkar JA et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2007; 13: 1236– 1245.Ziarkiewlcz-Wrobiewska B, Wroblewskl T, Wasiutynski A. Morphological features and differential diagnosis of hepatitis C recurrence after liver transplantation – literature review and results of single transplantation center. Ann Transplant. 2008; 13 (2): 12–20.Haga H, Miyagawa-Hayashino A, Taira K et al. Histological recurrence of autoimmune liver diseases after living-donor liver transplantation. Hepatol Res. 2007; 37: 463–469.Charatcharoenwitthaya P, Pimentel S, Talwalkar JA et al. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2007; 13: 1236– 1245.Hashimoto E, Taniai M, Yatsuji S et al. Long-term clinical outcome of living-donor liver transplantation for primary biliary cirrhosis. Hepatol Res. 2007; 37: 455–461. 43. Yamagiwa S, Ichida T. Recurrence of primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation in Japan. Hepatol Res. 2007; 37: 449– 454.Haga H, Miyagawa-Hayashino A, Taira K et al. Histological recurrence of autoimmune liver diseases after living-donor liver transplantation. Hepatol Res. 2007; 37: 463–469.Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl. 2009; 15 (Suppl 2): S25–34. doi: 10.1002/lt.21916.Hashimoto E, Taniai M, Yatsuji S et al. Long-term clinical outcome of living-donor liver transplantation for primary biliary cirrhosis. Hepatol Res. 2007; 37: 455–461. 43. Yamagiwa S, Ichida T. Recurrence of primary biliary cirrhosis and primary sclerosing cholangitis after liver transplantation in Japan. Hepatol Res. 2007; 37: 449– 454.Neuberger J. Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence. J Hepatol. 2003; 39: 142–148.Duclos-Vallee JC, Sebagh M. Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation. Liver Transpl. 2009; 15 (Suppl 2): S25–34. doi: 10.1002/lt.21916.Hytiroglou P, Gutierrez JA, Freni M et al. Recurrence of primary biliary cirrhosis and development of autoimmune hepatitis after liver transplant: A blind histologic study. Hepatol Res. 2009; 39 (6): 577–584.Neuberger J. Liver transplantation for primary biliary cirrhosis: indications and risk of recurrence. J Hepatol. 2003; 39: 142–148.Mendes F, Couto CA, Levy C. Recurrent and de novo autoimmune liver diseases. Clin Liver Dis. 2011; 15 (4): 859–878. doi: 10.1016/j.cld.2011.08.008.Hytiroglou P, Gutierrez JA, Freni M et al. Recurrence of primary biliary cirrhosis and development of autoimmune hepatitis after liver transplant: A blind histologic study. Hepatol Res. 2009; 39 (6): 577–584.Carbone M, Neuberger J. Liver transplantation in PBC and PSC: Indications and disease recurrence. Clin Res Hepatol Gastroenterol. 2011; 35: 446–454. doi: 10.1016/j.clinre.2011.02.007.Mendes F, Couto CA, Levy C. Recurrent and de novo autoimmune liver diseases. Clin Liver Dis. 2011; 15 (4): 859–878. doi: 10.1016/j.cld.2011.08.008.Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: Retrospective analysis of 400 patients in a single center. Hepatology. 2001; 33: 22–27.Carbone M, Neuberger J. Liver transplantation in PBC and PSC: Indications and disease recurrence. Clin Res Hepatol Gastroenterol. 2011; 35: 446–454. doi: 10.1016/j.clinre.2011.02.007.Kurdow R, Marks HG, Kraemer-Hansen H et al. Recurrence of primary biliary cirrhosis after orthotopic liver transplantation. Hepatogastroenterology. 2003; 50: 322– 325.Liermann Garcia RF, Evangelista Garcia C, McMaster P, Neuberger J. Transplantation for primary biliary cirrhosis: Retrospective analysis of 400 patients in a single center. Hepatology. 2001; 33: 22–27.Levitsky J, Hart J, Cohen SM, Te HS. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl. 2003; 9: 733–736.Kurdow R, Marks HG, Kraemer-Hansen H et al. Recurrence of primary biliary cirrhosis after orthotopic liver transplantation. Hepatogastroenterology. 2003; 50: 322– 325.Guy JE, Qian P, Lowell JA, Peters MG. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl. 2005; 11: 1252–1257.Levitsky J, Hart J, Cohen SM, Te HS. The effect of immunosuppressive regimens on the recurrence of primary biliary cirrhosis after liver transplantation. Liver Transpl. 2003; 9: 733–736.Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006; 12 (12): 1813– 1824.Guy JE, Qian P, Lowell JA, Peters MG. Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant. Liver Transpl. 2005; 11: 1252–1257.Kogiso T, Egawa H, Teramukai S, Taniai M, Hashimoto E et al. Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study. Hepatol Commun. 2017 May 16; 1 (5): 394–405. doi: 10.1002/ hep4.1037.Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl. 2006; 12 (12): 1813– 1824.Yamashiki N, Haga H, Ueda Y, Ito T, Yagi S et al. Use of Nakanuma staging and cytokeratin 7 staining for diagnosing recurrent primary biliary cholangitis after livingdonor liver transplantation. Hepatol Res. 2020 Apr; 50 (4): 478–487. doi: 10.1111/hepr.13476.Kogiso T, Egawa H, Teramukai S, Taniai M, Hashimoto E et al. Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study. Hepatol Commun. 2017 May 16; 1 (5): 394–405. doi: 10.1002/ hep4.1037.Sylvestre PB, Batts KP, Burgart LJ et al. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl. 2003; 9: 1086–1093.Yamashiki N, Haga H, Ueda Y, Ito T, Yagi S et al. Use of Nakanuma staging and cytokeratin 7 staining for diagnosing recurrent primary biliary cholangitis after livingdonor liver transplantation. Hepatol Res. 2020 Apr; 50 (4): 478–487. doi: 10.1111/hepr.13476.Egawa H, Sakisaka S, Teramukai S, Sakabayashi S, Yamamoto M, Umeshita K et al. Long-term outcomes of living-donor liver transplantation for primary biliary cirrhosis: a Japanese multi-center study. Am J Transplant. 2016; 16: 1248–1257.Sylvestre PB, Batts KP, Burgart LJ et al. Recurrence of primary biliary cirrhosis after liver transplantation: histologic estimate of incidence and natural history. Liver Transpl. 2003; 9: 1086–1093.Bosch A, Dumortier J, Maucort-Boulch D, Scoazec JY, Wendum D, Conti F et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. Journal of Hepatology. 2015; 63: 1449–1458. doi: 10.1016/j.jhep.2015.07.038.Egawa H, Sakisaka S, Teramukai S, Sakabayashi S, Yamamoto M, Umeshita K et al. Long-term outcomes of living-donor liver transplantation for primary biliary cirrhosis: a Japanese multi-center study. Am J Transplant. 2016; 16: 1248–1257.Schreuder TC, Hubscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int. 2009; 22: 144–152.Bosch A, Dumortier J, Maucort-Boulch D, Scoazec JY, Wendum D, Conti F et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. Journal of Hepatology. 2015; 63: 1449–1458. doi: 10.1016/j.jhep.2015.07.038.Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol. 2006; 101: 1370–1378.Schreuder TC, Hubscher SG, Neuberger J. Autoimmune liver diseases and recurrence after orthotopic liver transplantation: what have we learned so far? Transpl Int. 2009; 22: 144–152.Sanchez EQ, Levy MF, Goldstein RM et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation. 2003; 76: 1583–1588.Kotlyar DS, Campbell MS, Reddy KR. Recurrence of diseases following orthotopic liver transplantation. Am J Gastroenterol. 2006; 101: 1370–1378.Khettry U, Anand N, Faul PN, Lewis WD, Pomfret EA, Pomposelli J et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl. 2003; 9: 87–96.Sanchez EQ, Levy MF, Goldstein RM et al. The changing clinical presentation of recurrent primary biliary cirrhosis after liver transplantation. Transplantation. 2003; 76: 1583–1588.Montano-Loza AJ, Hansen BE, Corpechot C, Roccarina D, Thorburn D, Trivedi P et al. Global PBC Study Group. Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. Gastroenterology. 2019 Jan; 156 (1): 96–107.e1. doi: 10.1053/j.gastro.2018.10.001.Khettry U, Anand N, Faul PN, Lewis WD, Pomfret EA, Pomposelli J et al. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl. 2003; 9: 87–96.Grąt M, Lewandowski Z, Patkowski W, Wronka KM, Grąt K, Krasnodębski M et al. Relevance of male-tofemale sex mismatch in liver transplantation for primary biliary cirrhosis. Ann Transplant. 2015; 20: 116–123.Montano-Loza AJ, Hansen BE, Corpechot C, Roccarina D, Thorburn D, Trivedi P et al. Global PBC Study Group. Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. Gastroenterology. 2019 Jan; 156 (1): 96–107.e1. doi: 10.1053/j.gastro.2018.10.001.Morioka D, Egawa H, Kasahara M, Jo T, Sakamoto S, Ogura Y et al. Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis. Liver Transpl. 2007; 13: 80–90.Grąt M, Lewandowski Z, Patkowski W, Wronka KM, Grąt K, Krasnodębski M et al. Relevance of male-tofemale sex mismatch in liver transplantation for primary biliary cirrhosis. Ann Transplant. 2015; 20: 116–123.Balan V, Ruppert K, Demetris AJ, Ledneva T, Duquesnoy RJ, Detre KM et al. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Hepatology. 2008; 48: 878–888.Morioka D, Egawa H, Kasahara M, Jo T, Sakamoto S, Ogura Y et al. Impact of human leukocyte antigen mismatching on outcomes of living donor liver transplantation for primary biliary cirrhosis. Liver Transpl. 2007; 13: 80–90.Manousou P, Arvaniti V, Tsochatzis E, Isgro G, Jones K, Shirling G et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl. 2010; 16: 64–73.Balan V, Ruppert K, Demetris AJ, Ledneva T, Duquesnoy RJ, Detre KM et al. Long-term outcome of human leukocyte antigen mismatching in liver transplantation: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Hepatology. 2008; 48: 878–888.Hubscher SG, Portmann BC. Transplantation pathology. In: Burt A.D., Portmann B.C., Ferrell L.D. editors. MacSween’s Pathology of the Liver. 5th edn. London: Churchill Livingstone. 2007: 815–879.Manousou P, Arvaniti V, Tsochatzis E, Isgro G, Jones K, Shirling G et al. Primary biliary cirrhosis after liver transplantation: influence of immunosuppression and human leukocyte antigen locus disparity. Liver Transpl. 2010; 16: 64–73.Faust ThW. Recurrent Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, and Autoimmune Hepatitis After Transplantation. Liver Transplantation. 2001; 7 (11), Suppl 1: 99–108.Hubscher SG, Portmann BC. Transplantation pathology. In: Burt A.D., Portmann B.C., Ferrell L.D. editors. MacSween’s Pathology of the Liver. 5th edn. London: Churchill Livingstone. 2007: 815–879.Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Banff Working Group. Hepatology. 2006; 44 (2): 489–501. doi: 10.1002/hep.21280.Faust ThW. Recurrent Primary Biliary Cirrhosis, Primary Sclerosing Cholangitis, and Autoimmune Hepatitis After Transplantation. Liver Transplantation. 2001; 7 (11), Suppl 1: 99–108.Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Banff Working Group. Hepatology. 2006; 44 (2): 489–501. doi: 10.1002/hep.21280.Demetris AJ, Adeyi O, Bellamy CO, Clouston A, Charlotte F et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Banff Working Group. Hepatology. 2006; 44 (2): 489–501. doi: 10.1002/hep.21280.

The authors declare that there are no conflicts of interest present.